From gut to lung: Microbiota-derived metabolites reshaping the tumor immune microenvironment 

Prabesh Baniya et al.

EXCLI J. 2026 Aug 20;25:1383-1387. doi: 10.17179/excli2026-9646. eCollection 2026.

Published on October 7, 2026

Abstract

ABSTRACT

Lung cancer remains the leading cause of cancer-related mortality worldwide, and non- small cell lung cancer (NSCLC), which comprises the vast majority of lung cancer cases, has benefited from major therapeutic progress through targeted therapies and immune checkpoint inhibitors (ICIs). Although ICIs targeting the programmed cell death protein-1 (PD-1)/pro- grammed death-ligand 1 (PD-L1) axis have revolutionized the management of advanced NSCLC, only a subset of patients achieves durable clinical benefit, underscoring the urgent need to identify novel biomarkers and therapeutic strategies that can improve treatment effi- cacy. Emerging evidence indicates that the gut microbiota shapes the pulmonary tumor micro- environment, including in NSCLC (Jin et al., 2019).

PMID:42840252 | PMC:PMC13639179 | DOI:10.17179/excli2026-9646

 Read More

← Back to Publications
Saeka Shimochi et al.Pharmaceuticals (Basel). 2026 Oct 10;19(10):1610. doi: 10.3390/ph19101610.
Prince Dadson et al.Int J Obes (Lond). 2026 Oct 16. doi: 10.1038/s41366-026-02243-8. Online ahead of print.
Jiaqi Yan et al.Biomaterials. 2026 Sep 30;338(Pt A):124669. doi: 10.1016/j.biomaterials.2026.124669. Online ahead of print.
Hampus Grönvall et al.Brain Behav Immun Health. 2026 Sep 17;57:101365. doi: 10.1016/j.bbih.2026.101365. eCollection 2026 Nov.
Haifeng Xu et al.Mult Scler Relat Disord. 2026 Sep 24;115:107944. doi: 10.1016/j.msard.2026.107944. Online ahead of print.